Drug and Therapeutics Bulletin 1997;35:75-76; doi:10.1136/dtb.1997.351075
Copyright © 1997 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Donepezil for Alzheimer's disease?

Relevant BNF section: 4.11

Around 5% of people aged 65 years or more have dementia.1 In two-thirds of those affected, the underlying cause is Alzheimer's disease, a progressive form of dementia that may start in middle life. In the UK alone, the total cost of Alzheimer's disease is estimated to be over £1.5 billion per year.2 Traditionally, the mainstay of treatment has been supportive care. Here we assess the efficacy and safety of donepezil (Aricept - Eisai; Pfizer), an acetylcholinesterase inhibitor licensed in the UK earlier this year for the "symptomatic treatment of mild to moderately severe Alzheimer's dementia".




This article has been cited by other articles:


Home page
 BMJHome page
T. Greenhalgh, K. Stein, R. Milne, L. Best, H Boothby, S M N Zaidi, V Seth, S Khalaf, H Jameel, S Mahomed, et al.
Advertisements for donepezil
BMJ, December 13, 1997; 315(7122): 1623 - 1623.
[Full Text]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1997 BMJ Publishing Group Ltd.